Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed With Epilepsy
Conditions
Interventions
CB03-154
Locations
1
Australia
Alfred Health
Melbourne, Victoria, Australia
Start Date
August 14, 2025
Primary Completion Date
January 1, 2029
Completion Date
June 1, 2029
Last Updated
November 20, 2025
NCT07505004
NCT07219407
NCT06716801
NCT04653012
NCT05981755
NCT05100771
Lead Sponsor
Shanghai Zhimeng Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions